positive axillary lymph node

positive axillary lymph node

Oncology Lymph nodes in the axilla to which cancer has spread, a poor prognostic indicator in breast CA
References in periodicals archive ?
Group 1 consisted of patients with positive lymph node metastasis and extranodal tumor invasion; Group 2 consisted of patients with positive axillary lymph node metastasis and negative extranodal tumor invasion and Group 3 consisted of the patients with negative axillary lymph node metastasis.
Extracapsular extension in positive axillary lymph nodes in female breast cancer patients.
According to the stage of the disease, 20 patients (4.4%) presented with stage I of the disease, 158 (35.4%) with stage II out of which 58 presented with no axillary lymph node involvement and 100 patients presented with axillary lymph node involvement, 200 patients (44.8%) with stage III out of which 8 presented with negative axillary lymph nodes and 192 presented with positive axillary lymph nodes, and 68 patients (15.2%) with stage IV out of which 21 presented with no axillary lymph node involvement and 47 presented with positive axillary lymph nodes.
Out of 63 ER-positive cases, 25 had positive axillary lymph nodes, whereas out of 58 PR-positive cases 23 had positive axillary lymph nodes, and out of 7 HER2/neu-positive cases, 2 had positive axillary lymph nodes.
The 2001 American Society of Clinical Oncology clinical practice guideline on postmastectomy radiotherapy has been updated to help clinicians and patients decide which cases of T1-T2 breast cancer with one to three positive axillary lymph nodes will not benefit from the treatment.
Studies that are currently enrolling patients to address the benefit of axillary radiation in patients receiving neoadjuvant chemotherapy include the NSABP B-51 trial, which is evaluating patients with positive axillary lymph nodes prior to neoadjuvant chemotherapy who converted to pathologically negative lymph nodes after neoadjuvant chemotherapy, (24) and the Alliance A011202 trial, which is evaluating patients who have positive axillary lymph nodes before and after neoadjuvant chemotherapy.
Nonparametric variance analysis by Spearman's Rho ([rho]= 0.308, p<0.05) revealed a significant positive correlation between the tumor size and the number of positive axillary lymph nodes, meaning the larger the tumor the higher was the number of metastatic lymph nodes in the axilla.
One survey involved 160 medical oncologists faced with patients with ER-positive breast cancer with 1-3 positive axillary lymph nodes. In the 138 cases where the physician had a specific treatment recommendation before receiving the Oncotype DX results, the recommended regimen was changed from chemotherapy plus hormone therapy to hormone therapy alone in 46 patients (33%) based on the additional information provided by the recurrence score assay, reported Dr.
Online [1] in hormone receptor-positive operable breast cancer and 0-3 positive axillary lymph nodes treated with adjuvant chemohormonal therapy in a presentation by Lori Goldstein on behalf of the Eastern Cooperative Oncology Group (ECOG) and North American Cancer Intergroup (TBCI) (Abstr.
SAN ANTONIO -- The 70-gene profile known as the MammaPrint test is a powerful and independent prognostic marker in breast cancer patients who have one to three positive axillary lymph nodes, according to two studies presented at the annual San Antonio Breast Cancer Symposium.
Chemotherapy has benefited patients who have no sign of distant metastasis but who have positive axillary lymph nodes. Adjuvant chemotherapy typically is given to patients whose lymph nodes are positive or whose disease has recurred.
Three patients presenting with nipple discharge had positive axillary lymph nodes. There was no significant difference among the groups (p=0.137).
Full browser ?